Stem Cell Clinic

Stem Cell Therapy Market Current Trends and Future Growth Dagoretti News – Dagoretti News

Stem Cell Therapy Market

MARKET INTRODUCTION

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

MARKET DYNAMICSIncrease in the number of stem cell banking facilities and rising awareness on the benefits of stem cell for curing various disorders are expected to drive the market during the forecast period. Rise in number of regulations to promote stem cell therapy and increase in number of funds for research in developing countries are expected to offer growth opportunities to the market during the coming years.

Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100000991/

The key players influencing the market are:

This report contains:

The stem cell therapy market is segmented based on type as, adult stem cell, embryonic stem cell induced pluripotent stem cell and others. The adult stem cells segment is further segmented as hematopoietic, umbilical cord, neuronal and mesenchymal stem cells. Based on treatment, the market is categorized as allogeneic and autologous. The market is categorized by application as, muscoskeletal, dermatology, cardiology, drug discovery & development and others.

Stem Cell Therapy Market Global Analysis to 2027 is an expert compiled study which provides a holistic view of the market covering current trends and future scope with respect to product/service, the report also covers competitive analysis to understand the presence of key vendors in the companies by analyzing their product/services, key financial facts, details SWOT analysis and key development in last three years. Further chapter such as industry landscape and competitive landscape provides the reader with recent company level insights covering mergers and acquisitions, joint ventures, collaborations, new product developments/strategies taking place across the ecosystem. The chapters also evaluate the key vendors by mapping all the relevant products and services to exhibit the ranking/ position of top 5 key vendors.

Stem Cell Therapy Market is a combination of qualitative as well as quantitative analysis which can be broken down into 40% and 60% respectively. Market estimation and forecasts are presented in the report for the overall global market from 2018 2027, considering 2018 as the base year and 2018 2027 forecast period. Global estimation is further broken down by segments and geographies such as North America, Europe, Asia-Pacific, Middle East & Africa and South America covering major 16 countries across the mentioned regions. The qualitative contents for geographical analysis will cover market trends in each region and country which includes highlights of the key players operating in the respective region/country, PEST analysis of each region which includes political, economic, social and technological factors influencing the growth of the market.

Report Spotlights

Purchase This Report @ https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Semiconductors, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:Call: +1-646-491-9876Email: [emailprotected]

Read the original:
Stem Cell Therapy Market Current Trends and Future Growth Dagoretti News - Dagoretti News

Memphis Meats raises $161m to build its cell-based meat platform: ‘We have a pretty clear path to bringing prices down to cost parity’ -…

The Series B round led by SoftBank Group, Norwest and Temasek and supported by Richard Branson, Bill Gates, Threshold Ventures, Cargill, Tyson Foods, Finistere, Future Ventures, Kimbal Musk, Fifty Years, CPT Capital, KBW Ventures and Vulcan Capital will enable Memphis Meats to reach a historic milestone of bringing its products to consumers, said the Berkeley-based firm.

It also opens doors in Asia, a strategically valuable market for cell-based meat, added the company, which has now raised more than $180m since its launch in 2015.

This signifies our shift from a company focused on research to a company focused on bringing products to consumers, David Kay, senior manager of communications and operations told FoodNavigator-USA.

Memphis Meats has not announced a date for product launch, but will likely begin with premium-priced products in restaurants, which are great places to engage in meaningful conversations with chefs and consumers and get useful feedback, said Steve Myrick,VP of Operations.

"We have been very careful to develop our production system so we can produce multiple types of meat from multiple species on the same equipment, so the pilot plant will be animal agnostic. It may produce chicken in one run and beef the next. As to what comes to market first, it's still an open question for us. We've prototyped beef, chicken and duck, and we've worked on other things we haven't announced."

Asked about the price tag for the first wave of products, he said: "We believe we have a pretty clear path to bringing prices down to essentially conventional cost parity, and that will definitely take some time and some very meaningful scale above and beyond what we will be able to do in the pilot plant.

"That said, we don't intend to wait until we are price parity before we bring anything to consumers, because we think it is very important to have product out in the world and start collecting feedback and start educating consumers about what this is and why they should care about it.We believe we have a pretty clear path to bringing prices down to essentially conventional cost parity [with meat from slaughtered animals].

"I think we will bring products to market initially at prices that are at a premium to many other meat producers but hopefully not a very extreme one."

As for consumer sentiment around cell-based meat, survey findings can vary widely depending on how questions are phrased, but he added: "Most of the research has shown two thirds of consumers with a willingness to try or buy and we think that's a really attractive baseline number [given that research also shows enthusiam tends to increase the more educated consumers are on this topic]."

As to what investors were looking for in this round, Myricksaid they were focused on Memphis Meats' ability to prove its production system was scalable and capable of producing a consistent product, coupled with proof that costs were coming down in a meaningful way.

"We really showed that we had a clear path as we increased scale to bringing costs down to something that consumers will be able to afford."

When it comes to intellectual property, he said, "We think that we've done innovative work across three separate areas of our production system: the cells themselves, the cell culture feed or media, and the production system - the hardware in which we're producing meat, and across all three of those there is potential to protect our work through both patents and trade secrets."

Most cell-based meat startups have developed prototypes at the lab-scale, but when it comes to commercial viability, they need cell lines that can replicate/proliferate extensively or even indefinitely (without having to keep going back to the original source) and differentiate into multiple cells types such as muscle, fat and connective tissue. They also need a production process that enables these cells to grow rapidly, and an affordable growth medium that doesnt utilize fetal bovine serum (FBS), a byproduct of the livestock industry.

Myrick would not provide details on how Memphis Meats has brought down the cost ofFBS-freegrowth media, but added: "We've explored a number of strategies for understanding what FBS does in our process and then replacing some of the key components of that with components that are detached from slaughter."

Asked about the production process, VP of product and regulation Eric Schulze said the initial cell proliferation phase and the next differentiation phase could be conducted in the same vessel or in separate vessels, although the company is not providing details of its chosen approach at this stage.

Similarly, the different cell types (fat, muscle, connective tissue etc) can be grown separately and then combined at the processing stage at the end, or they can be grown together, he said. "We've explored both [approaches]and we use both regularly in our processes."

Quizzed on whether the company was using edible or biodegradable scaffolds upon which to seed cells in order to create more structured or 'steak-like' products, he said: "The cells themselves produce a scaffold and we primarily rely on the cells to do that but we continue to explore all options on the table."

Asked whether the company was using induced pluripotent stem cells (which behave like embryonic stem cells in that they can replicate/proliferate extensively without having to keep going back to the original source and differentiate into multiple cells types), he said:"All of our cells have the ability to self-renew and they are derived from muscle, fat, and connective tissue."

Asked about the regulatory framework for cell-based meat in the US, Schulze said Memphis Meats was working closely with the FDA and USDA, which have set up three working groups looking at safety, inspections and labeling (read more about this HERE).

The US government was moving"efficiently behind the scenes and publicly as well," he said.

As for terminology, in an ideal scenario, stakeholders will settle upon a term that can be used by regulators and consumers, said Schulze, who favors the 'factual and descriptive,' but also 'neutral' term 'cell-based meat' over other options such as 'cultivated' meat.

*Prior to this, the largest deal closed for the industry was BlueNalu's $20m Series A in September 2019. Future Meat Technologies had a $14m Series A in October 2019 and Memphis Meats had a $17m Series A in August 2017.

An investment of this magnitude if it is followed by a commercially available product at a reasonable price point sends a signal to the market that cell-cultured meatis here today rather than some far-off future endeavor,predicted Bruce Friedrich at the Good Food Institute, which promotes cell-cultured and plant-based meat.

This investment round is a monumental milestone in the progress of the field. This is the biggest investment of its kind for cultivated meat and will help Memphis Meats move toward the scale they will need to get their products to market.

But he added: This is still an industry that has sprung up almost overnight and its important to keep a sense of perspective here. While the idea of cultivated meat has been percolating for close to a century, the very first prototype was only produced six years ago.

Continued resources will be needed for years to come While private investments in cultivated meat are essential, they need to be supported by public funding in order to sustain the industry moving forward.

I am proud to invest once again in Memphis Meats, the world's leading cell-based meat company. In the next few decades I believe that cell-based meat will become a major part of our global meat supply. I cannot wait for that day!

Richard Branson

To meet the growing global demand for protein, it will take all of us working together we need both animal and cell-based. Our continued investment in Memphis Meats underscores our inclusive approach to the future of meat. We need all options on the table to meet customer and consumer needs now and in the future.

Elizabeth Gutschenritter, managing director, Cargills alternative protein team

Continued here:
Memphis Meats raises $161m to build its cell-based meat platform: 'We have a pretty clear path to bringing prices down to cost parity' -...